Search results
Results from the WOW.Com Content Network
EpiVacCorona, a peptide-based vaccine against COVID-19. IC41 is a peptide vaccine candidate against the Hepatitis C virus. It consists of five synthetic peptides along with the synthetic adjuvant called poly-l-arginine. [13] Multimeric-001 is the most efficient peptide vaccine candidate against influenza.
"Peptide immunogens and vaccine composition against coronavirus infection COVID-19 using peptide immunogens" (No. 2743593). The patented vaccine composition contains 2 peptides. "Peptide immunogens used as a component of a vaccine composition against coronavirus infection COVID-19" (No. 2743594). The patented vaccine composition contains 3 ...
The Moderna COVID‑19 vaccine, sold under the brand name Spikevax, is a COVID-19 vaccine developed by the American company Moderna, the United States National Institute of Allergy and Infectious Diseases (NIAID), and the Biomedical Advanced Research and Development Authority (BARDA).
Peptide therapeutics are peptides or polypeptides (oligomers or short polymers of amino acids) which are used to for the treatment of diseases. Naturally occurring peptides may serve as hormones , growth factors , neurotransmitters , ion channel ligands , and anti-infectives ; peptide therapeutics mimic such functions.
It cleaves the coronavirus polyprotein at eleven conserved sites. It is a cysteine protease and a member of the PA clan of proteases. It has a cysteine-histidine catalytic dyad at its active site and cleaves a Gln–(Ser/Ala/Gly) peptide bond. The Enzyme Commission refers to this family as SARS coronavirus main proteinase (M pro; EC 3.4.22.69).
An example of this is the facially cationic peptide C18G, which was designed from the C-terminal domain of human platelet factor IV. [70] Currently, the most widely used antimicrobial peptide is nisin ; being the only FDA approved antimicrobial peptide, it is commonly used as an artificial preservative.
The Pfizer–BioNTech COVID-19 vaccine is used to provide protection against COVID-19, caused by infection with the SARS-CoV-2 virus, by eliciting an immune response to the S antigen. [ 1 ] [ 2 ] [ 31 ] [ 40 ] The vaccine is used to reduce morbidity and mortality from COVID-19.
The CHMP's decision to start the rolling review is based on preliminary results from laboratory studies (non-clinical data) and early clinical studies in adults, which suggest that the vaccine triggers the production of antibodies that target SARS-CoV-2, the virus that causes COVID-19, and may help protect against the disease. [24]